Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Repligen's ebitda for the twelve months ending Sep 30, 2026 was $96.14M, up 23.3% year over year. For fiscal 2025 it was $133.91M, up 287.5% from the year before. Over ten years it grew 22.0% a year on average. The highest annual figure on record is $275.66M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.91M | +287.5% |
| FY2024 | Dec 31, 2024 | $34.56M | -70.3% |
| FY2023 | Dec 31, 2023 | $116.26M | -57.8% |
| FY2022 | Dec 31, 2022 | $275.66M | +34.0% |
| FY2021 | Dec 31, 2021 | $205.70M | +112.3% |
| FY2020 | Dec 31, 2020 | $96.89M | +70.1% |
| FY2019 | Dec 31, 2019 | $56.95M | +36.4% |
| FY2018 | Dec 31, 2018 | $41.77M | +70.4% |
| FY2017 | Dec 31, 2017 | $24.51M | +15.0% |
| FY2016 | Dec 31, 2016 | $21.31M | +16.1% |
| FY2015 | Dec 31, 2015 | $18.36M | +24.8% |
| FY2014 | Dec 31, 2014 | $14.71M | -43.4% |
| FY2013 | Dec 31, 2013 | $25.99M | +1898.3% |
| FY2011 | Mar 31, 2011 | $1.30M | – |
| FY2010 | Mar 31, 2010 | -$4.39M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$10.42M | -128.3% |
| Q2 FY2026 | Jun 30, 2026 | $33.04M | -2.8% |
| Q1 FY2026 | Mar 31, 2026 | $35.70M | +41.2% |
| Q4 FY2025 | Dec 31, 2025 | $37.82M | – |
| Q3 FY2025 | Sep 30, 2025 | $36.83M | +284.1% |
| Q2 FY2025 | Jun 30, 2025 | $33.98M | +51.4% |
| Q1 FY2025 | Mar 31, 2025 | $25.28M | +22.4% |
| Q4 FY2024 | Dec 31, 2024 | -$18.13M | -166.8% |
| Q3 FY2024 | Sep 30, 2024 | $9.59M | -60.9% |
| Q2 FY2024 | Jun 30, 2024 | $22.44M | -36.6% |
| Q1 FY2024 | Mar 31, 2024 | $20.66M | -29.3% |
| Q4 FY2023 | Dec 31, 2023 | $27.13M | -57.1% |
| Q3 FY2023 | Sep 30, 2023 | $24.51M | -62.5% |
| Q2 FY2023 | Jun 30, 2023 | $35.38M | -53.0% |
| Q1 FY2023 | Mar 31, 2023 | $29.23M | -59.3% |
| Q4 FY2022 | Dec 31, 2022 | $63.22M | +30.5% |
| Q3 FY2022 | Sep 30, 2022 | $65.34M | +18.4% |
| Q2 FY2022 | Jun 30, 2022 | $75.27M | +31.5% |
| Q1 FY2022 | Mar 31, 2022 | $71.83M | +60.2% |
| Q4 FY2021 | Dec 31, 2021 | $48.45M | +94.5% |
| Q3 FY2021 | Sep 30, 2021 | $55.20M | +99.5% |
| Q2 FY2021 | Jun 30, 2021 | $57.22M | +119.9% |
| Q1 FY2021 | Mar 31, 2021 | $44.83M | +145.0% |
| Q4 FY2020 | Dec 31, 2020 | $24.91M | +108.0% |
| Q3 FY2020 | Sep 30, 2020 | $27.67M | +102.0% |
| Q2 FY2020 | Jun 30, 2020 | $26.02M | +63.7% |
| Q1 FY2020 | Mar 31, 2020 | $18.30M | +18.9% |
| Q4 FY2019 | Dec 31, 2019 | $11.97M | +1.0% |
| Q3 FY2019 | Sep 30, 2019 | $13.70M | +16.4% |
| Q2 FY2019 | Jun 30, 2019 | $15.89M | +93.7% |
| Q1 FY2019 | Mar 31, 2019 | $15.38M | +54.8% |
| Q4 FY2018 | Dec 31, 2018 | $11.86M | +60.3% |
| Q3 FY2018 | Sep 30, 2018 | $11.77M | +337.4% |
| Q2 FY2018 | Jun 30, 2018 | $8.21M | +14.5% |
| Q1 FY2018 | Mar 31, 2018 | $9.94M | +36.9% |
| Q4 FY2017 | Dec 31, 2017 | $7.40M | +68.3% |
| Q3 FY2017 | Sep 30, 2017 | $2.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.17M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.40M | – |
See a number that looks wrong?